Senores Pharmaceuticals Limited has informed the Exchange regarding Resignation of Senior Management Personnel of the Company
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals has announced two changes to its Senior Management Personnel (SMP), both effective March 17, 2026. Mr. Jatin Gajjar, the company's Chief Technology Officer, has been formally categorized as an SMP on the recommendation of the Nomination and Remuneration Committee. Mr. Manohar Lalge, President – Research and Development, has tendered his resignation and will cease to be an SMP from the close of business hours on March 17, 2026. Mr. Gajjar brings over three decades of experience in pharmaceutical technology, having held leadership roles at Amneal, Sun Pharma, Alembic, Zydus Cadila, Torrent Pharma, and Aventis Pharma. The changes were approved by the Board via a circular resolution. No reason for the resignation was disclosed beyond Mr. Lalge's personal letter submitted in January 2026.
The departure of the R&D President is a notable leadership change that could raise short-term concerns about continuity in the company's research pipeline, though the CTO's formal elevation provides some stability in the technology and product development function. Investors will watch for any further disclosures on succession planning for the R&D head.